These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 10561254

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial.
    Boccardo F, Barichello M, Battaglia M, Carmignani G, Comeri G, Ferraris V, Lilliu S, Montefiore F, Portoghese F, Cortellini P, Rigatti P, Usai E, Rubagotti A, Italian Prostate Cancer Group.
    Eur Urol; 2002 Nov; 42(5):481-90. PubMed ID: 12429158
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
    Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G.
    Urology; 1996 Jan; 47(1A Suppl):54-60; discussion 80-4. PubMed ID: 8560679
    [Abstract] [Full Text] [Related]

  • 6. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.
    Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Schellenger JJ, Kolvenbag GJ.
    Urology; 1997 Sep; 50(3):330-6. PubMed ID: 9301693
    [Abstract] [Full Text] [Related]

  • 7. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.
    Soloway MS, Schellhammer P, Sharifi R, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G.
    Eur Urol; 1996 Sep; 29 Suppl 2():105-9. PubMed ID: 8717471
    [Abstract] [Full Text] [Related]

  • 8. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.
    Chodak G, Sharifi R, Kasimis B, Block NL, Macramalla E, Kennealey GT.
    Urology; 1995 Dec; 46(6):849-55. PubMed ID: 7502428
    [Abstract] [Full Text] [Related]

  • 9. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [Abstract] [Full Text] [Related]

  • 10. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.
    Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T, Chamberlain M, Carroll K, Gotting-Smith K, Blackledge GR.
    Urology; 1998 Mar; 51(3):389-96. PubMed ID: 9510340
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development.
    Kolvenbag GJ, Blackledge GR, Gotting-Smith K.
    Prostate; 1998 Jan 01; 34(1):61-72. PubMed ID: 9428389
    [Abstract] [Full Text] [Related]

  • 13. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
    Chu FM, Sartor O, Gomella L, Rudo T, Somerville MC, Hereghty B, Manyak MJ.
    Eur J Cancer; 2015 Aug 01; 51(12):1555-69. PubMed ID: 26048455
    [Abstract] [Full Text] [Related]

  • 14. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
    Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, Chamberlain M, Carroll K, Melezinek I.
    J Urol; 2000 Nov 01; 164(5):1579-82. PubMed ID: 11025708
    [Abstract] [Full Text] [Related]

  • 15. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
    Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, Kolvenbag G, Shapiro L, Schwartz M.
    J Clin Oncol; 1997 Aug 01; 15(8):2928-38. PubMed ID: 9256137
    [Abstract] [Full Text] [Related]

  • 16. Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group.
    McLeod DG, Schellhammer PF, Vogelzang NJ, Soloway MS, Sharifi R, Block NL, Venner PM, Patterson AL, Sarosdy MF, Kelley RP, Kolvenbag GJ.
    Prostate; 1999 Sep 01; 40(4):218-24. PubMed ID: 10420149
    [Abstract] [Full Text] [Related]

  • 17. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
    Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Chen Y, Kolvenbag GJ.
    Cancer; 1996 Nov 15; 78(10):2164-9. PubMed ID: 8918410
    [Abstract] [Full Text] [Related]

  • 18. [The role of bicalutamide in the treatment of prostate cancer].
    Stav SY, Segal G.
    Harefuah; 2002 Apr 15; 141(4):379-83, 408, 407. PubMed ID: 12017896
    [Abstract] [Full Text] [Related]

  • 19. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
    Di Lorenzo G, Perdonà S, De Placido S, D'Armiento M, Gallo A, Damiano R, Pingitore D, Gallo L, De Sio M, Autorino R.
    J Urol; 2005 Dec 15; 174(6):2197-203. PubMed ID: 16280763
    [Abstract] [Full Text] [Related]

  • 20. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H, Hara I, Eto H.
    BJU Int; 2005 Oct 15; 96(6):791-5. PubMed ID: 16153202
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.